Amsidine (amsacrine) / Kyowa Kirin - LARVOL DELTA

Deciphering the Dysregulated Pathways and Candidate Therapeutic Compounds for Primary Ovarian Cancer Using Whole Transcriptomics Data and Next Generation Knowledge Discovery Strategies. (PubMed, J Cell Mol Med) - "Based on NGKD analysis, we identified approximately 50 synthetic or natural compounds, including naproxol, palbociclib, etoposide, wortmannin, PP-110, AZD-8055, amsacrine and BRD-K6595526. The results of this study could aid in the development of personalized treatment plans based on the unique profile of each tumour type, thus facilitating the development of personalized or precision treatment plans and improving diagnostic and prognostic capabilities in the clinic. In conclusion, the combination of RNA-seq and cutting-edge NGKD methodologies holds significant promise for identifying key cellular and molecular pathways and OC therapeutics."

IO biomarker • Journal • Epithelial Ovarian Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • TGFB1

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (clinicaltrials.gov) - P1/2 | N=38 | Recruiting | Sponsor: Heinrich-Heine University, Duesseldorf | Trial completion date: Jan 2028 ➔ Apr 2029 | Trial primary completion date: Jan 2026 ➔ Apr 2029

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • DEK • IDH1 • IDH2 • KMT2A • KRAS • NF1 • NRAS • NUP214 • PTPN11 • RIT1 • RUNX1 • TP53

Daratumumab in Combination With High-Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T-Cell Acute Lymphoblastic Leukemia: A Case Report. (PubMed, Pediatr Blood Cancer) - "Daratumumab, an anti-CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T-ALL. We report here the achievement of a third complete response with the combination of daratumumab, high-dose cytarabine (18 g/m2), and amsacrine in an 11-year-old patient with highly aggressive relapsed T-ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation

Amsacrine modifies action potential configuration without its prolongation via the blockade of multiple ion currents in canine ventricular cells. (PubMed, Biomed Pharmacother) - "It contains methanesulfonamide group -similar to hERG/IKr inhibitors like E-4031 and dofetilide-therefore may exert cardiac arrhythmias...Amsacrine reduced phase 0 parameters: maximal upstroke velocity (∼50-60%), action potential amplitude (∼15%), and peak potential (∼55%), suggesting inhibition of sodium current...The lack of AP prolongation despite IKr inhibition can be due to concomitant suppression of inward currents. As the tested concentrations overlap with therapeutic plasma levels (3-18 µM), amsacrine may carry a non-negligible risk of cardiac electrophysiological effects, particularly in susceptible patients."

Journal • Acute Lymphocytic Leukemia • Cardiovascular • Hematological Malignancies • Leukemia • Oncology • NAV1

Circumvention of acquired resistance to topoisomerase II-targeted anticancer agents in HL-60 leukemia cells by prevention of intronic polyadenylation. (PubMed, J Pharmacol Exp Ther) - "The resulting splice site gene-edited clone, designated MX2/SS-Edit, expressed reduced TOP2α/160 mRNA/protein, increased TOP2α/170 mRNA/protein, and exhibited partial restoration of sensitivity to mitoxantrone, etoposide, and amsacrine. SIGNIFICANCE STATEMENT: Results presented here validated drug resistance in the HL-60/MX2 leukemia cell line driven by intronic polyadenylation (IPA) within intron 33 of the DNA topoisomerase IIα (TOP2α) gene, which produced a truncated and predominantly cytoplasmic TOP2α protein isoform (TOP2α/160). Using CRISPR/Cas9/homology-directed repair gene editing, the weak exon 33/intron 33 5' splice site was enhanced to suppress IPA, which restored expression of full-length protein (TOP2α/170) and led to a gain-of-function in drug sensitivity, offering a potential strategy to overcome drug resistance."

Journal • Preclinical • Hematological Malignancies • Leukemia • Oncology • MX2 • TOP2A

Cross-Species Transcriptomic and Network Analysis of Human and Canine Diffuse Large B-Cell Lymphoma Identifies a Conserved Replication-DNA Damage Module for Drug Repurposing. (PubMed, Vet Comp Oncol) - "Querying the Connectivity Map/LINCS library with the human component of the module highlighted anthracycline-like topoisomerase II poisons (valrubicin, etoposide, amsacrine) and the PARP inhibitor rucaparib among the ~0.2% most negative connectivity scores, while directly targeting TOP2A and/or PARP1. Finally, extracellular-vesicle microRNA (EV-miRNA) profiling in human DLBCL showed that differentially expressed EV-miRNAs, including let-7 family members, miR-21-5p, miR-124-3p and miR-205-5p, converge on the same TOP2A/PARP1-centred core. These cross-species, multi-layer data support topoisomerase II poisons and PARP inhibition as coherent, network-anchored candidate therapies for canine DLBCL, with module scores and EV-miRNAs as candidate biomarkers."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MIR124-3 • MIR205 • MIR21 • TOP2A

Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling. (PubMed, Front Pharmacol) - "The identification of known Wnt inhibitors such as emetine, tyrphostin A9, niclosamide, ouabain, and podophyllotoxin further validated the assay's robustness. Collectively, this study establishes a robust 1536-well screening platform for identifying Wnt pathway modulators and identifies topotecan, amsacrine, brefeldin A, and tyrphostin AG 879 as candidate small-molecule antagonist, thereby expanding the chemical tools for investigating Wnt/β-catenin signaling."

Journal • CNS Disorders • Fibrosis • Immunology • Oncology

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial (ASH 2025) - "Using a classical 3+3 design, patientsreceived escalating doses of Venetoclax starting on day -11, one day before a 4-day treatment withFLAMSA (day -10 to -7, Fludarabine 30 mg/m2/day, Amsacrine 100 mg/m2/day and Cytarabine 2 g/m2/day,1 g/m2/day for patients older than 60 years)...Allogeneic peripheral blood stem cellswere infused on day 0 and GvHD prophylaxis consisted of tacrolimus, mycophenolate mofetil and a totaldose of 30 mg/kg ATG. A total of 9 patients (3 female) at a median age of 62 years (range 56 - 69) were included in thephase I part of the study (6 MDS, 2 CMML, 1 AML, all having active disease and unfavorable biology).Three patients received a total daily dose of 200 mg, 3 of 400 mg, 2 of 800 mg and 1 of 1600 mgVenetoclax in combination with FLAMSA... Smart conditioning using Venetoclax up to a daily dose of 800 mg in addition to FLAMSA-Treosulfan is safe. Hematopoietic reconstitution was not impaired and general toxicity of this sequentialconditioning..."

Clinical • P1/2 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • CD34

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study (ASH 2025) - P | "Anotheroption for maintenance therapy in these patients is oral azacitidine (AZA) as demonstrated in a post-hocanalysis of the phase 3 QUAZAR AML-001 trial (Döhner et al, Blood, 2022).Methods...In all, 80 (53.7%) receivedintensive therapy (median age 68.5y, 60-78) while 60 (40.3%) underwent a non-intensive treatment,mainly AZA plus venetoclax for 81% of them (median age 77y, 64-98); 3 received best supportive care and6 died before treatment initiation...Intensiveapproaches were as follows: 7+3 for 57 (81%), CPX-351 for 11 (16%), 7+3 plus GO for one patient (1%) andamsacrine/cytarabine for the last patient (1%). Specifically in the 7+3 subcohort, the majority received7+3 with midostaurin (n=39, 68%; idarubicin 28, daunorubicin 11); 17 were treated without midostaurin(30%; ida 11, dauno 6)...In this analysis, allotransplantation (HR, 0.09 [95% CI,0.01-0.78]; p=0.029) or maintenance therapy with midostaurin/gilteritinib (HR, 0.17 [95% CI, 0.03-0.93]; p=0.041) were..."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • NPM1

KRAS-Driven Hypertranscription and Metastatic Dissemination in Colorectal Cancer Could be Overcome by Targeting the NMHC IIA/ PLK1 Signaling Axis with a Novel Acridine Derivative. (PubMed, Int J Biol Sci) - "A large-scale drug screen of 786 Food and Drug Administration (FDA)-approved anticancer agents identified the acridine compound amsacrine hydrochloride as a potent inhibitor of PDOs and cell lines...This inhibition disrupts the PI3K/ERK/FOXO/PLK1 signaling pathway and attenuates KRAS-driven hypertranscription. In conclusion, the acridine derivative LS-1-2 emerges as a promising candidate from this preclinical investigation, providing a rationale for future clinical trials in KRAS-mutant CRC."

Journal • Colorectal Cancer • Oncology • Solid Tumor • KRAS • MYH9 • PLK1

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH) (ASH 2023) - "In France, lomustine was added to 7+3 in patients >60 years. The most frequent second-line therapy in the whole IC population was salvage chemotherapy with high-dose or intermediate-dose cytarabine or a combination of either of these with anthracycline (daunorubicin, idarubicin, or amsacrine) in France and decitabine or the combination of cytarabine, etoposide and mitoxantrone in the USA. Azacitidine/venetoclax combination was used in second and third line in France and USA and it was the most frequent third-line therapy (35.8%) in France. Patients received IC in combination with targeted therapies (mainly midostaurin) in 18% of the IC population in France and 12.4% of the IC population in the USA...In the REAL-IDH study we observed that treatment patterns in mIDH1 or wild type patients were similar. More specific data is needed regarding the sequencing of treatment regimens and overall outcomes in mIDH1 AML patients."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Septic Shock • IDH1

The Role of Small Nucleolar RNAs As Putative Biomarkers of Chemoresistance in Pediatric Acute Lymphoblastic Leukemia (ASH 2023) - "05 and absolute log2FC>1) in the high-resistance group for one or multiple drugs: amsacrine (ams, n = 10), etoposide (eto, n = 10), tioguanine (thio, n = 8) and mitoxantrone (mito, n = 1). Importantly, our analysis indicates that the differential expression of snoRNAs in the resistance groups cannot be solely attributed to host gene expression, implying that targeting pathways involving host genes might not be the most effective approach. Rather than concentrating on pathways involving host genes, our results suggest that understanding the mechanisms of action of snoRNAs could provide promising avenues for developing novel therapeutic targets to enhance drug response in pediatric ALL."

Biomarker • Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • SNHG1

Targeting Loss of the Tumor Suppressor TENT5C in Multiple Myeloma (ASH 2023) - "Inhibitors targeting the cell cycle (roscovitine, apigenin, SP60012) and angiogenesis (amsacrine) were selected for validation and further investigation. Our results indicate a tumor suppressor role of TENT5C in MM, with antiproliferative properties and a susceptibility to spliceosome and NHEJ inhibitors. The HTP screen identified other targets that are currently undergoing validation leading to the identification of the molecular mechanisms underlying this function."

Hematological Malignancies • Multiple Myeloma • Oncology • NT5C • TENT5C

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients (ASH 2023) - " This retrospective study from the Department of Stem Cell Transplantation at the University Medical Center Hamburg, Germany, compared allo-SCT outcomes in CMML patients across three conditioning regimes: Thiotepa-Busulfan (TB), Sequential FLAMSA-Busulfan Fludarabine (FLAMSA-FB), and Treosulfan-Fludarabine (Treo-Flu)...FLAMSA-FB regimen consists of fludarabine (30 mg/m2; total dose 120 mg/m2 ), amsacrine (100 mg/m2; total dose 400 mg/m 2 ), and cytarabine (1 g/m2; total dose 4 g/m 2 ) therapy from days -11 to minus -8, followed by a three-day interval without therapy and Busulfan from day -4 to -2 with a total dose of 6.4mg/Kg and Fludarabine on day -4 and -3 (30 mg/m2, total dose 60mg/m 2 ).Treo-Flu regimen consisted of Treosulfan (12 g/m2 , total dose 36 mg/m2 ) on days-6 to -4 and fludarabine (30 mg/m2; total dose 150 mg/m2 ) on days -6 to -2...Lastly, cumulative incidences of acute GVHD grade II-IV (TB 41%, FLAMSA-FB 35%, Treo-Flu 30%, p=0.75) and all-grade chronic..."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Immunology • Transplantation

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial (ASH 2024) - "Subjects with AML in CR1 (n=45) or CR2 (n=47) were conditioned with a myeloablative regiment consisting of Busulfan (age adjusted i.v. dosing : 3.2 – 4,8 mg/kg BW on days -7 through -4), Cyclophosphamide (60mg/kg i.v. on days -3 and -2), and Melphalan (140 mg/m2 i.v. on day -1) (BuCyMel). Graft-versus-Host disease (GvHD) prophylaxis was cyclosporine (CSA) and short-term methotrexate...Patients with poor response to AML induction therapy (n=48) were stratified to receive a reduced-intensity regimen consisting of a cytoreductive block with Fludarabine (30mg/m2/d i.v.), Amsacrine (100 mg/m2/d i.v.), and Cytarabine (2g/m2/d i.v.) (FLAMSA) on days -12 through -9, immediately followed by 4 Gy TBI on day -5 and Cyclophosphamide (60 (unrelated)/40 (related) mg/kg/day i.v.) on days -4 through -3...CONCLUSION : With improving HLA-typing technology, OS and CI of chronic and acute GvHD II-IV are identical after MUD- and MSD-transplantation for pediatric AML, if ATLG is added for..."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups (ASH 2024) - P2/3 | "In case of CR, the HSCT protocol strategy recommended a Seq FLAMSA (Fludarabine 30 mg/m2, high-dose cytarabine 2 g/m2, and amsacrine 100 mg/m2) followed by a RIC regimen (Busulfan 6.4 mg/kg and cyclophosphamide 100 mg/kg) from matched sibling donor (MSD), 10/10 (MUD) or 9/10 (MMUD) unrelated donors. GvHD prophylaxis consisted in rabbit ATG 5 mg/kg with CsA plus MMF...Conclusion : The 5-yrs OS of 41.2% compares favorably with published results. While a Seq regimen did not improve HSCT outcomes, best results were obtained in younger pts with adv risk AML in CR at time of HSCT irrespective of graft source for those transplanted less than 6 months after AML diagnosis."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation

Synthesis, in-silico and in-vitro evaluation of quinoline-chromene hybrids as dual topoisomerase inhibitors. (PubMed, Bioorg Med Chem) - "Molecular docking experiments performed on topoisomerase I (3QX3) and II (4FM9) showed high binding affinities with lead molecules 6c, 6l, and 6j having greater efficacy in comparison to standard agents camptothecin and amsacrine...Structure-activity relationship (SAR) analysis showed that substituents with an electron-donating effect increased π-π stacking and hydrogen bonding and associated well with enhanced potency and selectivity. Collectively, these results position quinoline-chromene hybrids as important leads in anticancer treatment and emphasize the advantages of scaffold hybridization in attaining efficient, selective, and mechanistically established inhibition of the topoisomerase."

Journal • Preclinical • Oncology • TOP1

Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML-A Population-Based Study. (PubMed, Eur J Haematol) - "Secondary AML and adverse ELN risk were associated with worse OS after salvage ICT, while fludarabine-based FAIDA versus amsacrine-based ACE salvage and HSCT were associated with better OS. In conclusion, refractory AML patients eligible for further intensive therapy have a reasonable chance of obtaining remission and long-term survival when followed by HSCT. The results can serve as a basis for evaluation of new treatments in refractory AML."

Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation

DEXAML-03: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - P3 | N=73 | Terminated | Sponsor: University Hospital, Toulouse | N=142 ➔ 73 | Trial completion date: Dec 2025 ➔ May 2024 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2025 ➔ May 2024; Despite a recruitment target that was not met, we managed to achieve more than 50% of inclusions and 33% of deaths, enabling us to carry out an initial analysis of the primary endpoint

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

IMPROVED LONG TERM SURVIVAL OF PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES AFTER UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION WITH SEQUENTIAL CONDITIONING – ADDITION OF VENETOCLAX PROLONGS RFS (EBMT 2025) - "The FLAMSA- (Fludarabine/Amsacrine/Ara-C) protocol, which has already been modified multiple times, was last amended by adding venetoclax, an inhibitor of B-Cell Lymphoma-2 that has synergistic effects to chemotherapy, without increasing non-hematologic toxicity... In this retrospective survey, we identified 53 patients (median age 61 years, range 20 - 74, 20 female) with myeloid malignancies (43 MDS, 7 AML, 3 CMML) who had received either FLAMSA (27 patients) or FLAMSAClax (26 patients) + Alkylator (Melphalan or Treosulfan) based between 2018 and 2023...ATG was used in 40 (75.5%) and post-transplant cyclophosphamide (ptCy) in 8 patients (15.1%) in addition to GvHD prophylaxis with Tacrolimus or CSA and MMF... Upfront allografting in patients with high-risk myeloid malignancies can achieve overall survival rates of around 80% at 2 years while the addition of Venetoclax to FLAMSA + Alkylator prolongs relapse-free survival. With median time to relapse of 691 days after..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Oncology • Transplantation • BCL2

SEQUENTIAL FLAMSA-FB CONDITIONING IMPROVES PFS IN UNTREATED MDS PATIENTS UNDERGOING ALLOGENEIC HSCT COMPARED TO ALTERNATIVE REGIMENS (EBMT 2025) - "Forty-five received FLAMSA and 61 alternative conditioning: TB (n=30), FB (n=16), or Treo-Flu (n=15).FLAMSA: Fludarabine 30 mg/m²/day (total 120 mg/m²), amsacrine 100 mg/m²/day (total 400 mg/m²), and cytarabine 1 g/m²/day (total 4 g/m²) on days -11 to -8, followed by a 3-day break. Then busulfan 6.4 mg/kg (days -4 to -3) plus fludarabine 30 mg/m² (total 60 mg/m²) for FLAMSA-FB or busulfan 6.4 mg/kg for FLAMSA-Bu.TB: Thiotepa 5 mg/kg/day (total 10 mg/kg; days -6, -5) and busulfan 3.2 mg/kg/day (total 6.4 or 9.6 mg/kg; days -4, -3 for >60 years or days -4 to -2 for ≤60 years).Treo-Flu: Treosulfan 12 g/m²/day (total 36 g/m²; days -6 to -4) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -6 to -2).FB: Busulfan 6.4 mg/kg (days -7 to -5) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -7 to -3)... In untreated MDS patients undergoing allo-SCT, the sequential FLAMSA-FB regimen improved PFS compared..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Leukemia • Myelodysplastic Syndrome

SEQUENTIAL FLAMSA-FB CONDITIONING IMPROVES PFS IN UNTREATED MDS PATIENTS UNDERGOING ALLOGENEIC HSCT COMPARED TO ALTERNATIVE REGIMENS (EBMT 2025) - "Forty-five received FLAMSA and 61 alternative conditioning: TB (n=30), FB (n=16), or Treo-Flu (n=15).FLAMSA: Fludarabine 30 mg/m²/day (total 120 mg/m²), amsacrine 100 mg/m²/day (total 400 mg/m²), and cytarabine 1 g/m²/day (total 4 g/m²) on days -11 to -8, followed by a 3-day break. Then busulfan 6.4 mg/kg (days -4 to -3) plus fludarabine 30 mg/m² (total 60 mg/m²) for FLAMSA-FB or busulfan 6.4 mg/kg for FLAMSA-Bu.TB: Thiotepa 5 mg/kg/day (total 10 mg/kg; days -6, -5) and busulfan 3.2 mg/kg/day (total 6.4 or 9.6 mg/kg; days -4, -3 for >60 years or days -4 to -2 for ≤60 years).Treo-Flu: Treosulfan 12 g/m²/day (total 36 g/m²; days -6 to -4) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -6 to -2).FB: Busulfan 6.4 mg/kg (days -7 to -5) and fludarabine 30 mg/m²/day (total 150 mg/m²; days -7 to -3)... In untreated MDS patients undergoing allo-SCT, the sequential FLAMSA-FB regimen improved PFS compared..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Leukemia • Myelodysplastic Syndrome

LONG-TERM SURVIVAL AFTER SEQUENTIAL CONDITIONING WITH FLAMSA AND TOTAL BODY IRRADIATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2025) - "Major improvement for deep remission was observed in Philadelphia positive (BCR-ABL) as well as negative b-precursor ALL with the introduction of tyrosine kinase inhibitors as well as Blinatumomab and Inotuzumab...Of Patients with B-ALL 33% were Philadelphia chromosome positive.In this subgroup analysis we report the outcome of 28 patients (14 B-ALL, 14 T-ALL, 71% male, 29% female, median age at transplant 29 years, range 17-61) who received a sequential conditioning regimen containing Fludarabin, Amsacrine, high-dose Cytarabine (FLASMA) combined with Total Body Irradiation (TBI) of 8-12 Gy... Even in high-risk groups and especially in patients with T-ALL sequential conditioning containing FLAMSA and TBI results in remarkable long-term survival with a manageable toxicity profile."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • BCR

LONG-TERM SURVIVAL AFTER SEQUENTIAL CONDITIONING WITH FLAMSA AND TOTAL BODY IRRADIATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2025) - "Major improvement for deep remission was observed in Philadelphia positive (BCR-ABL) as well as negative b-precursor ALL with the introduction of tyrosine kinase inhibitors as well as Blinatumomab and Inotuzumab...Of Patients with B-ALL 33% were Philadelphia chromosome positive.In this subgroup analysis we report the outcome of 28 patients (14 B-ALL, 14 T-ALL, 71% male, 29% female, median age at transplant 29 years, range 17-61) who received a sequential conditioning regimen containing Fludarabin, Amsacrine, high-dose Cytarabine (FLASMA) combined with Total Body Irradiation (TBI) of 8-12 Gy... Even in high-risk groups and especially in patients with T-ALL sequential conditioning containing FLAMSA and TBI results in remarkable long-term survival with a manageable toxicity profile."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • BCR

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL (clinicaltrials.gov) - P2/3 | N=745 | Completed | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Active, not recruiting ➔ Completed

Trial completion • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics